124 related articles for article (PubMed ID: 9593702)
1. Activation of the human immunodeficiency virus long terminal repeat by varicella-zoster virus IE4 protein requires nuclear factor-kappaB and involves both the amino-terminal and the carboxyl-terminal cysteine-rich region.
de Maisieres PD; Baudoux-Tebache L; Merville MP; Rentier B; Bours V; Piette J
J Biol Chem; 1998 May; 273(22):13636-44. PubMed ID: 9593702
[TBL] [Abstract][Full Text] [Related]
2. Gene activation by Varicella-zoster virus IE4 protein requires its dimerization and involves both the arginine-rich sequence, the central part, and the carboxyl-terminal cysteine-rich region.
Baudoux L; Defechereux P; Rentier B; Piette J
J Biol Chem; 2000 Oct; 275(42):32822-31. PubMed ID: 10889190
[TBL] [Abstract][Full Text] [Related]
3. Amino acid analogs activate NF-kappaB through redox-dependent IkappaB-alpha degradation by the proteasome without apparent IkappaB-alpha phosphorylation. Consequence on HIV-1 long terminal repeat activation.
Kretz-Remy C; Bates EE; Arrigo AP
J Biol Chem; 1998 Feb; 273(6):3180-91. PubMed ID: 9452429
[TBL] [Abstract][Full Text] [Related]
4. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
Beauparlant P; Kwon H; Clarke M; Lin R; Sonenberg N; Wainberg M; Hiscott J
J Virol; 1996 Sep; 70(9):5777-85. PubMed ID: 8709193
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of the HIV-1 LTR by specific NF-kappa B subunits in HSV-1-infected cells.
Schafer SL; Hiscott J; Pitha PM
Virology; 1996 Oct; 224(1):214-23. PubMed ID: 8862416
[TBL] [Abstract][Full Text] [Related]
6. Regulation of HIV-1 long terminal repeats by interaction of C/EBP(NF-IL6) and NF-kappaB/Rel transcription factors.
Ruocco MR; Chen X; Ambrosino C; Dragonetti E; Liu W; Mallardo M; De Falco G; Palmieri C; Franzoso G; Quinto I; Venuta S; Scala G
J Biol Chem; 1996 Sep; 271(37):22479-86. PubMed ID: 8798413
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies.
Quivy V; Adam E; Collette Y; Demonte D; Chariot A; Vanhulle C; Berkhout B; Castellano R; de Launoit Y; Burny A; Piette J; Bours V; Van Lint C
J Virol; 2002 Nov; 76(21):11091-103. PubMed ID: 12368351
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
[TBL] [Abstract][Full Text] [Related]
9. Essential role of NF-kappa B in transactivation of the human immunodeficiency virus long terminal repeat by the human cytomegalovirus 1E1 protein.
Kim S; Yu SS; Kim VN
J Gen Virol; 1996 Jan; 77 ( Pt 1)():83-91. PubMed ID: 8558131
[TBL] [Abstract][Full Text] [Related]
10. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
[TBL] [Abstract][Full Text] [Related]
11. Hiv-1 Tat can substantially enhance the capacity of NIK to induce IkappaB degradation.
Li X; Josef J; Marasco WA
Biochem Biophys Res Commun; 2001 Aug; 286(3):587-94. PubMed ID: 11511100
[TBL] [Abstract][Full Text] [Related]
12. T-cell activation leads to poor activation of the HIV-1 clade E long terminal repeat and weak association of nuclear factor-kappaB and NFAT with its enhancer region.
Lemieux AM; Paré ME; Audet B; Legault E; Lefort S; Boucher N; Landry S; van Opijnen T; Berkhout B; Naghavi MH; Tremblay MJ; Barbeau B
J Biol Chem; 2004 Dec; 279(51):52949-60. PubMed ID: 15466412
[TBL] [Abstract][Full Text] [Related]
13. Intracellular distribution of the ORF4 gene product of varicella-zoster virus is influenced by the IE62 protein.
Defechereux P; Debrus S; Baudoux L; Schoonbroodt S; Merville MP; Rentier B; Piette J
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1505-13. PubMed ID: 8757993
[TBL] [Abstract][Full Text] [Related]
14. Kaposi's sarcoma associated herpes virus-encoded viral FLICE inhibitory protein activates transcription from HIV-1 Long Terminal Repeat via the classical NF-kappaB pathway and functionally cooperates with Tat.
Sun Q; Matta H; Chaudhary PM
Retrovirology; 2005 Feb; 2():9. PubMed ID: 15713234
[TBL] [Abstract][Full Text] [Related]
15. I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding.
Ganchi PA; Sun SC; Greene WC; Ballard DW
Mol Biol Cell; 1992 Dec; 3(12):1339-52. PubMed ID: 1493333
[TBL] [Abstract][Full Text] [Related]
16. Lack of responsiveness of a nuclear factor-kappaB-regulated promoter to transactivation by human immunodeficiency virus 1 Tat in HeLa cells.
Kelly GD; Morris CB; Offermann MK
Virology; 1999 Oct; 263(1):128-38. PubMed ID: 10544088
[TBL] [Abstract][Full Text] [Related]
17. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53.
Subler MA; Martin DW; Deb S
J Virol; 1994 Jan; 68(1):103-10. PubMed ID: 8254719
[TBL] [Abstract][Full Text] [Related]
18. An NF-kappaB site in the 5'-untranslated leader region of the human immunodeficiency virus type 1 enhances the viral expression in response to NF-kappaB-activating stimuli.
Mallardo M; Dragonetti E; Baldassarre F; Ambrosino C; Scala G; Quinto I
J Biol Chem; 1996 Aug; 271(34):20820-7. PubMed ID: 8702837
[TBL] [Abstract][Full Text] [Related]
19. TAR and Sp1-independent transactivation of HIV long terminal repeat by the Tat protein in the presence of human cytomegalovirus IE1/IE2.
Dal Monte P; Landini MP; Sinclair J; Virelizier JL; Michelson S
AIDS; 1997 Mar; 11(3):297-303. PubMed ID: 9147420
[TBL] [Abstract][Full Text] [Related]
20. Influenza virus-induced NF-kappaB-dependent gene expression is mediated by overexpression of viral proteins and involves oxidative radicals and activation of IkappaB kinase.
Flory E; Kunz M; Scheller C; Jassoy C; Stauber R; Rapp UR; Ludwig S
J Biol Chem; 2000 Mar; 275(12):8307-14. PubMed ID: 10722660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
